Today: 29 June 2026
Browse Category

LSE:GSK 30 July 2025 - 10 December 2025

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance.Stock Titan+1 Below is a deep dive into today’s news, how GSK shares are trading, what analysts are forecasting, and where the risk/reward balance looks to be heading into 2026. This is information, not personalised investment advice.
10 December 2025
···
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

As of 9 December 2025, GSK plc stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and largely defused one of the biggest litigation overhangs in the sector. On the NYSE, GSK ADRs change hands around $48–49, very near their 52‑week high of $49.31, and up roughly 37% over the past year, versus about 14% for the S&P 500 over the same period. Yahoo Finance+1 On the London Stock Exchange, GSK trades around £18.0, also just below its 52‑week high near £18.5 and well above the 52‑week low around £12.4. London Stock Exchange+1
9 December 2025
···
GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)

GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)

GSK plc’s share price is pressing against 52‑week highs as 2025 draws to a close, with investors weighing a cluster of near‑term FDA decisions, a major CEO change on 1 January 2026, and a still‑busy share buyback programme. As of 4 December 2025, GSK shares on the London Stock Exchange trade at 1,836.5p, within a day range of 1,827–1,839p and a 52‑week range of 1,242.5–1,848.5p.Investing.com The New York–listed ADR closed on 3 December at $48.97, just below its 52‑week high of $49.31 and well above its 52‑week low of $31.72.Investing.com
4 December 2025
··
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts are still only lukewarm on the stock, and long‑term growth expectations lag management’s ambitions. This is a deep dive into where GSK stock stands today, what’s driving the rally, and what current news and forecasts are signalling about 2026 and beyond.
3 December 2025
·
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of 2 December 2025, the stock sits close to its 52‑week peak while analyst opinion remains broadly neutral and focused on whether the pipeline can deliver enough growth to meet GSK’s ambitious 2031 revenue targets. Hargreaves Lansdown+2Yahoo Finance+2 This overview pulls together the key share‑price moves, fresh news from 2 December, Street forecasts and the main bull and bear arguments around GSK stock as of today.
2 December 2025
····
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete, investor-focused look at what’s moving GSK right now. The biggest GSK headline today comes from Washington: Medicare has released the second round of negotiated prices for 15 of its costliest prescription medicines, with two GSK respiratory products on the list. Newsweek+3Reuters+3pharmaphorum+3
26 November 2025
··
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

London, 20 November 2025 — GSK plc finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop. Based on end‑of‑day data from Hargreaves Lansdown, GSK closed the London session at around 1,776p, a gain of about 0.23% versus Wednesday’s close of 1,772.5p. The stock opened at 1,778p, touched an intraday high near 1,790.3p, and briefly dipped to about 1,772p before settling in the mid‑1,770s. Hargreaves Lansdown
20 November 2025
··
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025

As London investors get ready for the opening bell on Monday, 17 November 2025, GSK plc is entering the week in a strong but finely balanced position: the shares sit close to their 52‑week highs, the company has just gone ex‑dividend, buybacks are running hard, guidance has been upgraded, key drugs have hit major regulatory milestones – and legacy Zantac litigation is easing but not gone. Here’s a concise but detailed look at what matters for GSK’s share price before the market opens.
16 November 2025
··
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month high intraday. BioSpace+2 AN2 Therapeutics announced a collaboration with GSK to advance boron‑based leucyl‑tRNA synthetase inhibitors for tuberculosis. The effort is supported by a third year of Gates Foundation funding and builds on prior work between AN2 scientists and GSK’s Global Health R&D team, according to the release. Thomas Breuer, GSK’s Chief Global Health Officer, framed the partnership as aligning with the company’s goal to “get ahead” of TB in lower‑income countries. BioSpace
11 November 2025
···
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Key Facts: European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added 0.16% to 9,299.84 aa.com.tr. France’s CAC 40 rose 0.13% to 7,880.87. By contrast, Italy’s FTSE MIB and Spain’s IBEX 35 both fell about 0.22% on the day aa.com.tr. Across the Atlantic, U.S. stock futures were little changed, reflecting caution ahead of key U.S. developments.
30 September 2025
······
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% reuters.com. France’s CAC 40 and Germany’s DAX each gained a few tenths of a percent reuters.com. Major indices in Southern Europe also edged up. Across sectors, the strongest gains were in healthcare and tech, offsetting weakness in commodity-linked areas and automakers. Several high-profile company announcements drove individual stocks on Monday. In pharmaceuticals, GSK jumped ~3.5% after announcing that long-time CEO Emma Walmsley will step down at year-end, handing over to COO Luke Miels reuters.com. A market commentator noted GSK shares had been lagging peers, and the new leadership “is a bet the market likes for now” standard.co.uk. AstraZeneca also moved higher when it said it will list ordinary shares directly in New York to attract more US investors, while keeping its London and Stockholm listings reuters.com. CEO Pascal Soriot and CFO Chris Demarest emphasized the change “will allow us to reach a broader mix of global investors” reuters.com.
29 September 2025
·······
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org. Another study this week revealed a promising cardiovascular benefit from vaccination. An analysis presented at the European Society of Cardiology Congress found that getting the shingles vaccine is associated with significantly lower rates of heart attacks and strokes reuters.com. Pooled data from nine studies
30 August 2025
····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com. “Making America Healthy Again” or Undermining Science?: The narrower vaccine rollout comes amid turmoil at the CDC. CDC Director Dr. Susan Monarez was fired on Aug. 27, just weeks into the job, after clashing with HHS Secretary Robert F. Kennedy Jr. over his sweeping vaccine policy changes reuters.com reuters.com. Kennedy –
28 August 2025
····
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

This 48-hour period brought a flurry of major developments in biotechnology, pharmaceuticals, medicine and public health worldwide – from game-changing clinical trial victories and regulatory decisions to urgent health policy actions and scientific breakthroughs. Below is a comprehensive roundup of the top news from August 10–11, 2025. Sources: Recent press releases, Reuters and Bloomberg industry news, WHO and CDC announcements, and articles in ScienceDaily, Cell Reports Medicine, Microbiology Spectrum, and other peer-reviewed journals reuters.com cancernetwork.com reuters.com reuters.com novartis.com sciencedaily.com. Each development above is linked to its original source for further reading. Stay tuned as more late-breaking news unfolds in the fast-moving health and biopharma arena.
11 August 2025
····
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung Unveils Thinner Foldables: Samsung launched its latest foldable smartphones – the Galaxy Z Fold7 and Galaxy Z Flip7 – touting them as the thinnest, lightest iterations yet. The premium Galaxy Z Fold7 now starts at $1,999, while a new cheaper Flip7 FE comes in at $899 reuters.com. Both devices sport slimmer profiles to address past bulkiness reuters.com. Analysts say the refinements help Samsung fend off growing competition from Chinese rivals in the niche foldables market reuters.com. The company is even teasing a tri-foldable phone by year’s end reuters.com, signaling Samsung’s aggressive roadmap for foldable consumer electronics innovation. Opera’s Antitrust Complaint: In software news, Norwegian browser-maker Opera escalated its rivalry with Microsoft by filing an antitrust complaint in Brazil. Opera alleges Microsoft gives its Edge browser an unfair edge by pre-installing it as the default on Windows, hindering competition reuters.com reuters.com. “Microsoft thwarts browser competition on Windows at every turn… and then frustrates users’ ability to download and use alternative browsers,” Opera’s general counsel Aaron McParlan said in a statement reuters.com. Microsoft had no immediate comment on the complaint.
30 July 2025
·············
1 2 3 4

Stock Market Today

  • SPS Commerce (SPSC) Rallies 5.7% on Sale Rumors, Earnings in Focus
    June 29, 2026, 2:05 PM EDT. SPS Commerce (SPSC) closed up 5.7% at $58.87 after volume spiked and reports spread about a possible sale, tied to activist pressure for the company to consider strategic options. The supply chain software firm forecasts quarterly EPS of $1.08, up 8% from last year, and sees revenue at $195.14 million, up 4.1%. Consensus estimates for earnings didn't move in the last 30 days, which could cap upside ahead. SPSC sits at Zacks Rank #2 (Buy). Bowman Consulting (BWMN), another name in the group, climbed 2.3% but has seen its earnings estimates drop 14.6%; Zacks Rank is #3 (Hold). Market watching for shifts in earnings outlooks for clues on next moves.
Go toTop